Orchid Pharma Q4 FY26 Earnings Update

Orchid Pharma reported Q4 FY26 revenue of ₹238 crore, largely stable compared to ₹237 crore in Q4 FY25. EBITDA for the quarter increased to ₹42.3 crore from ₹40 crore in the previous year.

For the full fiscal year FY26, standalone revenue stood at ₹811 crore, a decrease from ₹922 crore in FY25. Standalone EBITDA for FY26 was ₹101 crore, down from ₹155 crore in FY25. Dhanuka Labs contributed ₹450 crore in revenue in FY26, compared to ₹500 crore in FY25.

Reader Takeaway: Stabilization in Q4 revenue and EBITDA, with strategic growth initiatives in progress.

What just happened

Orchid Pharma announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a stable revenue of ₹238 crore for Q4 FY26, with a marginal improvement in EBITDA to ₹42.3 crore.

Full-year FY26 revenue declined to ₹811 crore from ₹922 crore in FY25. Management highlighted advanced discussions for out-licensing its Enmetazobactam product in several key geographies and expects commissioning of its 7ACA project in Q1 CY2027.

Why this matters

The Q4 results indicate a potential stabilization after a challenging fiscal year. The company's strategic focus on out-licensing Enmetazobactam and developing the 7ACA project could drive future growth. The ongoing merger with Dhanuka Laboratories aims to create a unified anti-infective platform.

The backstory

Orchid Pharma has been working on strengthening its product pipeline and manufacturing capabilities. The Enmetazobactam development and licensing efforts are crucial for expanding its global presence. The 7ACA project is a key backward integration initiative. The proposed merger with Dhanuka Laboratories is intended to achieve synergistic benefits.

What changes now

With Q4 results showing stability, the company is poised to focus on executing its strategic plans. Key near-term events include securing licensing deals for Enmetazobactam, completing the Dhanuka Laboratories merger upon receiving the court order, and advancing the 7ACA project towards its commissioning.

Risks to watch

Management noted pricing pressures in non-regulated markets, requiring weekly price reviews. The merger with Dhanuka Laboratories is pending a formal court order, introducing execution risk. The 7ACA project is described as a 'race against time', emphasizing the need for strict adherence to commissioning timelines.

Peer comparison

• Dhanuka Labs: The merger aims to combine Orchid Pharma's established presence with Dhanuka Labs' revenue contribution (₹450 crore in FY26).
• Orchid Pharma's focus on specialized anti-infectives and R&D differentiates it in the pharmaceutical sector.

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹238 crore (vs. ₹237 crore in Q4 FY25)
• Q4 FY26 EBITDA: ₹42.3 crore (vs. ₹40 crore in Q4 FY25)
• FY26 Revenue: ₹811 crore (vs. ₹922 crore in FY25)
• FY26 EBITDA: ₹101 crore (vs. ₹155 crore in FY25)
• FY27 Base Business Growth Target: 10% to 15%
• 7ACA Project Commissioning: Expected Q1 CY2027

What to track next

Investors will be closely watching the finalization of the Dhanuka Laboratories merger, progress on Enmetazobactam out-licensing deals, and the timely commissioning of the 7ACA project. Performance against the FY27 growth guidance will also be a key indicator.